A number of research firms have changed their ratings and price targets for C.R. Bard (NYSE: BCR):
- 7/19/2017 - C.R. Bard was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
- 7/17/2017 - C.R. Bard was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the past one year, C. R. Bard has outperformed the broader industry trends with respect to price performance. However we feel the stock offers limited value to investors in the near term owing to it trading around $320 per share which is above Becton, Dickinson’s takeover price of $317 per share. The $24 billion transaction is expected to close by fall 2017. Looking forward C. R. Bard is expected to benefit from the impending merger, especially in the areas of medication management and infection prevention. We believe the development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters. However, a challenging Med-tech environment is a major concern. The company witnesses significant pricing pressure as well.”
- 7/11/2017 - C.R. Bard had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $317.00 price target on the stock.
- 7/8/2017 - C.R. Bard was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
- 6/21/2017 - C.R. Bard was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $353.00 price target on the stock. According to Zacks, “Shares of the company returned higher than the broader industry in the last twelve months. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close by fall 2017. We believe the latest development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. Further the company has gained prominence in the market with an expanding product portfolio and continuing regulatory approvals. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters. “
- 6/20/2017 - C.R. Bard was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Shares of the company returned higher than the broader industry in the last twelve months. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close by fall 2017. We believe the latest development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. Further the company has gained prominence in the market with an expanding product portfolio and continuing regulatory approvals. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters. “
- 6/13/2017 - C.R. Bard was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $351.00 price target on the stock. According to Zacks, “Shares of the company returned higher than the broader industry in the last twelve months. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close by fall 2017. We believe the latest development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. Further the company has gained prominence in the market with an expanding product portfolio and continuing regulatory approvals. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters. “
- 6/12/2017 - C.R. Bard was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Shares of the company returned higher than the broader industry in the last twelve months. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close by fall 2017. We believe the latest development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. Further the company has gained prominence in the market with an expanding product portfolio and continuing regulatory approvals. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters. “
- 6/6/2017 - C.R. Bard was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $351.00 price target on the stock. According to Zacks, “Shares of the company returned higher than the broader industry in the last twelve months. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close by fall 2017. We believe the latest development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. Further the company has gained prominence in the market with an expanding product portfolio and continuing regulatory approvals. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters. “
Shares of C.R. Bard, Inc. (BCR) traded down 0.13% during midday trading on Friday, reaching $320.99. The company’s stock had a trading volume of 1,087,535 shares. The stock has a market capitalization of $23.25 billion, a PE ratio of 40.85 and a beta of 0.59. The stock has a 50-day moving average price of $317.37 and a 200 day moving average price of $276.95. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $323.27.
C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. The firm had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.54 earnings per share. Equities analysts forecast that C.R. Bard, Inc. will post $11.78 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 4th. Investors of record on Monday, July 24th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a yield of 0.32%. C.R. Bard’s payout ratio is 13.21%.
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for CR Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CR Bard Inc and related companies with MarketBeat.com's FREE daily email newsletter.
